Schultz and his University of Iowa collaborators also received an Iowa Neuroscience Institute Accelerator Grant to extend their work into Huntington's disease. Specifically, Schultz’s team will explore the acute effects of terazosin on ATP levels in the brain. They expect their research to significantly enhance understanding of the connection between energy production and neurodegeneration and to lay the groundwork for future studies aimed at modifying the disease course of Huntington’s disease.
Research on terazosin, a drug used to treat enlarged prostate, may also slow the progression of Parkinson's disease, according to Jordan Schultz, assistant professor, '13 PharmD, Jacob Simmering, research assistant, '16 PhD, and their collaborators. Their research was published in The Journal of Clinical Investigation and is also discussed here.